HMG CoA reductase inhibitor therapy underused after CAGB

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.364, 2002-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cerivastatin: the low-dose HMG-COA reductase inhibitor

By Tikkanen M.J.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 161-166

Informa Healthcare

Access to resources Recommend Favorite

Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

A switch from current HMG CoA reductase inhibitor [statin] therapy to either cerivastatin 0.4 or 0.8 mg/day or simvastatin 80 mg/day

Inpharma, Vol. 1, Iss. 1307, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The HMG CoA reductase inhibitor [statin] atorvastatin [`Lipitor'; Pfizer], has garnered a Q3 sales increase

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 339, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite